Novo Nordisk’s next obesity battlefront: Winning beyond America
Novo Nordisk is facing challenges in the obesity drug market despite an early lead with its Wegovy pill. The company expects a decline in profits and sales due to lower prices and competition from generics. Meanwhile, Eli Lilly's rival product Foundayo has seen slower adoption compared to Wegovy, which is gaining popularity in the U.S.
- ▪Novo Nordisk forecasts a sales decline of 4% to 12% in 2026.
- ▪Wegovy has surpassed 2 million total prescriptions since its U.S. launch.
- ▪Eli Lilly's Foundayo has recorded fewer prescriptions than Wegovy since its launch.
CNBC — Top files mainly under finance. We currently carry 510 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | CNBC — Top |
| Canonical URL | https://www.cnbc.com/2026/05/18/novo-nordisk-wegovy-pill-launch-eli-lilly-foundayo-weight-loss.html |
| Publication time | Mon, 18 May 2026 05:00:01 GMT |
| Retrieval time | 2026-05-18T05:04:56.107Z |
| Last seen | 2026-05-18T05:04:56.107Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | cvXtZ6hoRKQw |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
While Eli Lilly expects sales to grow 28% at the midpoint of its guidance this year, Novo has forecast a drastic decline in sales.Novo hiked its guidance slightly last week, but still expects profits and sales to decline between 4% and 12% in 2026, hurt by lower prices in the U.S. and generic competition in markets including India, Canada, Brazil, and China.This is despite Novo gaining an early lead in the oral weight loss drugs with the U.S. launch of the Wegovy pill in January. Last week, Novo said total prescriptions had reached more than 2 million, as sales massively beat expectations in its first quarter despite its lower price point.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at CNBC — Top.
Discussion
0 commentsMore from CNBC — Top
